Flamel Technologies SA (FLML) Shares Up 4.1%
Flamel Technologies SA (NASDAQ:FLML) shot up 4.1% on Wednesday . The company traded as high as $13.00 and last traded at $12.99, with a volume of 97,921 shares traded. The stock had previously closed at $12.48.
A number of research firms have recently weighed in on FLML. Leerink Swann reissued an “outperform” rating and set a $16.00 target price on shares of Flamel Technologies SA in a report on Wednesday, March 23rd. Zacks Investment Research raised Flamel Technologies SA from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $18.63.
The company has a market capitalization of $526.65 million and a price-to-earnings ratio of 24.19. The company’s 50-day moving average price is $10.69 and its 200-day moving average price is $10.44.
Flamel Technologies SA (NASDAQ:FLML) last issued its quarterly earnings data on Monday, May 9th. The company reported $0.04 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.14 by $0.10. The firm earned $36.20 million during the quarter, compared to analysts’ expectations of $34 million. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, analysts expect that Flamel Technologies SA will post ($0.03) EPS for the current year.
In other Flamel Technologies SA news, Director Craig R. Stapleton acquired 27,228 shares of the business’s stock in a transaction dated Monday, May 16th. The shares were purchased at an average cost of $9.21 per share, for a total transaction of $250,769.88. Following the transaction, the director now owns 507,263 shares in the company, valued at $4,671,892.23. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael S. Anderson purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 12th. The shares were purchased at an average price of $8.84 per share, for a total transaction of $44,200.00. Following the completion of the transaction, the chief executive officer now directly owns 134,250 shares of the company’s stock, valued at $1,186,770. The disclosure for this purchase can be found here.
Several large investors have recently added to or reduced their stakes in FLML. Russell Frank Co raised its stake in Flamel Technologies SA by 15.5% in the fourth quarter. Russell Frank Co now owns 422,247 shares of the company’s stock valued at $6,118,000 after buying an additional 56,752 shares in the last quarter. Turner Investments L.P. raised its stake in Flamel Technologies SA by 77.3% in the fourth quarter. Turner Investments L.P. now owns 239,308 shares of the company’s stock valued at $2,922,000 after buying an additional 104,340 shares in the last quarter. Sei Investments Co. purchased a new stake in Flamel Technologies SA during the fourth quarter valued at $2,129,000. Heartland Advisors Inc. purchased a new stake in Flamel Technologies SA during the fourth quarter valued at $3,053,000. Finally, Morgan Stanley raised its stake in Flamel Technologies SA by 131.4% in the fourth quarter. Morgan Stanley now owns 719,463 shares of the company’s stock valued at $8,785,000 after buying an additional 408,531 shares in the last quarter.
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.